JZL184
From Self-sufficiency
Revision as of 14:28, 30 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s): cannabinoid-stub)
| JZL184 | |
|---|---|
| File:Jzl184 2structures.png | |
| 4-nitrophenyl-4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C27H24N2O9 |
| Molar mass | 520.15 g/mol |
| Appearance | Pale yellow solid |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
JZL184 is an irreversible inhibitor for monoacylglycerol lipase (MAGL), the primary enzyme responsible for degrading the endocannabinoid 2-arachidonoylglycerol (2-AG).[1] It displays high selectivity for MAGL over other brain serine hydrolases, including the anandamide-degrading enzyme fatty acid amide hydrolase (FAAH), thereby making it a useful tool for studying the effects of endogenous 2-AG signaling, in vivo. Administration of JZL184 to mice was reported to cause dramatic elevation of brain 2-AG leading to several cannabinoid-related behavioral effects.
References
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
| 40px | This article about a cannabinoid is a stub. You can help ssf by expanding it. |
| 40px | This medical treatment-related article is a stub. You can help ssf by expanding it. |
